5-HT_2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine

The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia

1987 • 19,723 citations

A Diagnostic Interview

1978 • 5,735 citations

The Global Assessment Scale

1976 • 4,944 citations

A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS

1970 • 3,213 citations

A Rating Scale for Drug-Induced Akathisia

1989 • 2,135 citations

The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations

1989 • 1,384 citations

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1996 • 1,143 citations

Serotonin-dopamine interaction and its relevance to schizophrenia

1996 • 822 citations

Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia

1989 • 600 citations

Serotonin receptors in the human brain—III. Autoradiographic mapping of serotonin-1 receptors

1987 • 569 citations

Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol

1995 • 558 citations

Serotonin receptors in the human brain—IV. Autoradiographic mapping of serotonin-2 receptors

1987 • 342 citations

Association between clozapine response and allelic variation in 5-HT2A receptor gene

1995 • 330 citations

Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia

1992 • 207 citations

The New Atypical Antipsychotics

1994 • 168 citations

Assessment of Tardive Dyskinesia Using the Abnormal Involuntary Movement Scale

1985 • 168 citations

Binding of Antipsychotic Drugs to Cortical 5-HT_2A Receptors: A PET Study of Chlorpromazine, Clozapine, and Amisulpride in Schizophrenic Patients

1998 • 125 citations

Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels

1997 • 99 citations

Noradrenaline and 5‐hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease.

1983 • 84 citations

Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia

1997 • 82 citations

Positron Emission Tomography of in-vivo Binding Characteristics of Atypical Antipsychotic Drugs

1996 • 78 citations

Serotonin function and treatment response to clozapine in schizophrenic patients

1993 • 68 citations

Radiosynthesis of a new radioiodinated ligand for serotonin‐5HT₂‐receptors, a promising tracer for γ‐emission tomography

1994 • 52 citations

Initial evaluation of123I-5-I-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects

1997 • 46 citations

Initial evaluation of123|-5-|-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects

1997 • 40 citations

The split-dose technique for the study of psychological and pharmacological activation with the cerebral blood flow marker 99m-Tc-exametazime and single photon emission computed tomography (SPECT): reproducibility and rater reliability

1991 • 35 citations

Effect of Clozapine on d-Fenfluramine-Evoked Neuroendocrine Responses in Schizophrenia and its Relationship to Clinical Improvement

1995 • 33 citations

DIPHTHERIA IN INOCULATED PERSONS

1942 • 1 citations